Similarly, in lung cancer, radioresistance-related signatures also predict patient outcomes and immune status (31), identifying TOP2A, CDH3, ASPM, CENPF, SLC2A1, and PRC1 as potential detection biomarkers for early lung cancer (32). Here, PRC1 is linked to lung cancer.